U.S. 3D Bioprinting Market

To learn more about this report, Download Free Sample Report

U.S. 3D Bioprinting Market Size

The U.S. 3D bioprinting market was valued at USD 385 million in 2025. The market is estimated at USD 437.67 million in 2026 and is projected to reach USD 1,221 million by 2034, growing at a CAGR of 13.68% from 2026 to 2034.

The growing pharmaceutical industry, growing drug development activities, and increasing prevalence of chronic diseases in the U.S. are propelling the 3D bioprinting market in the United States. Drug development needs significant investment, and the return on investment depends upon the success of the drug in the respective market. There were cases where some of the drugs incurred losses to the investors. To reduce such losses, 3D bioprinting is used for new drug development. Bio-printed tissue is used in the early stage of drug development to provide cost-effective solutions in the development process. It helps the researcher to determine the possibility and save time and money. 3D bioprinting gives more profit to the pharmaceutical industry. This is because drug development is a significant task in every pharmaceutical industry. Based on a recent survey, the U.S. government has invested nearly 2.6 million U.S. dollars in developing the new drug.

The growing scarcity of organ donors in the United States is accelerating the growth of the 3D bioprinting market in the U.S. As per the statistics published by Donate Life America, nearly 8,000 Americans on the waiting list die each year due to a lack of donors for donations. In addition, many people suffering from kidney, heart, and liver damage are waiting for organ donation to save their lives. As a result, researchers are developing 3D temporary organ structures, known as scaffolds, that help regenerates damaged tissues and potentially lead to the creation of artificial organs. This 3D bioprinting involves blood vessels, bone, cartilage, heart, kidneys, skin, and neurons. This 3D bioprinting process uses the patient's cells to create the 3D printed organs, which reduces the risk of donor organs being rejected by the body.

Using 3D bioprinting in cosmetology is also boosting market growth. Recently one of the new developments in 3D bioprinter cosmetology is human hair. The bioprinter skin has specific compositional and functional factors. Therefore, it helps in the faster development of the products with the help of this 3D bioprinting. Increasing advancements in 3D bioprinting in different applications, increasing research and development of 3D bioprinting in different sectors, increasing product approvals, and increasing investment by the government are the other factors that drive the market forward during the forecast period. In addition, the Increasing use of sensor-based systems and artificial intelligence in this 3D bioprinting also drives the market forward. 3D bioprinting is also used for creating bone, cardiovascular, cartilage, corneal and neural constructs in animal species. Most researchers are focusing on the veterinary field and reducing the cost of 3D bioprinting products for animals.

However, the primary factor restraining the market growth is the high development and maintenance costs associated with 3D bioprinting. In addition, a lack of skilled professionals, a lack of regulatory approvals, and a lack of infrastructure in some regions may hamper the market growth.

This research report on the U.S. 3D bioprinting market has been segmented & sub-segmented into material type, technologies, components, applications, and country.

By Component

• 3D Bioprinters
  • Microextrusion bioprinting
  • Inkjet 3D Bioprinting
  • Laser-assisted Bioprinting
  • Magnetic 3D Bioprinting
  • Other technologies
• Bio inks
  • Natural Bio inks
  • Hybrid Bio inks
  • Synthetic Bio inks

By Application

• Research Applications

  • Drug Research
  • Regenerative Medicine
  • 3D Cell Culture
• Clinical Application
  • Skin
  • Bone & Cartilage
  • Blood Vessels
  • Other Clinical Applications

By End User

• Research Organization & Academic Institutes

• Biopharmaceuticals Companies
• Hospital

By Country

• United States

The U.S. had the leading share of the global 3D bioprinting market in 2021. The USFDA ensures the safety of these biological products, drugs, and medical products that are 3D printed. Therefore, approving this product takes more time to reduce the risk for the patient using them.

The Canadian region is another prominent location in the North American market and is anticipated to showcase a healthy CAGR during the forecast period. Companies operating in this location focus on developing various bioprinting products and creating awareness around bioprinting among people. In 2021, Health Canada approved the first Canadian-made 3D-printed medical implant. These devices are customizable for facial surgery. These 3D-printed medical implants are mainly used for people who have oral cancer.

KEY MARKET PLAYERS

Notable companies operating in the U.S. 3D bioprinting market profiled in this report are Advanced Solutions Life Sciences, Allevi Inc., Aspect Biosystems Ltd., Cellink, Cyfuse Biomedical K.K., Digilab, Inc., Envisiontec, Gesim, Nano3D Biosciences, Inc., Organovo Holdings, Inc., Poietis, Regenhu, Regenovo Biotechnology Co., Ltd., Rokit Healthcare and Tevido Biodevices.